PCSK9 and Hypercholesterolemia: Currently, CVI Pharmaceuticals is recruiting participants for a phase 2 clinical trial to further assess the effectiveness of CVI-LM001 for hypercholesterolemia treatment (NCT04438096).382 Moreover, Wang et al. recently reported a compound DC371739 which suppressed PCSK9 mRNA expression and reduced the plasma levels of total cholesterol (TC), LDL-C, and TG in animal models, and DC371739 showed preliminary positive results in a phase 1 trial (NCT04927221).414 (Table 2).